Clinical Trial Update: Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating azimilide to reduce cardiovascular hospitalizations, emergency department visits, or cardiovascular death in patients with an implant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arrhythmia
• Cardiovascular Disease
• Heart Disease

Drugs mentioned

• Azimilide (azimilide)

Snippet

Sponsor: Forest Laboratories | Conditions: Arrhythmias, Cardiac, Heart Diseases | Phase 3 | Status: TERMINATED